These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9413682)

  • 1. Global regulatory considerations for unified assay specifications.
    Patterson S; Lin L; Elchico J; Fuchs R; Powell S; Redhair D; Warwick M; Solli N; Méndez B
    Dev Biol Stand; 1997; 91():45-8. PubMed ID: 9413682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 6. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of assay validation in specification development.
    Baffi RA
    Dev Biol Stand; 1997; 91():105-13. PubMed ID: 9413687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriate specifications at the IND stage.
    Geigert J
    Dev Biol Stand; 1997; 91():39-43. PubMed ID: 9413681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology.
    Thorpe R; Wadhwa M; Mire-Sluis A
    Dev Biol Stand; 1997; 91():79-88. PubMed ID: 9413686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raw material considerations.
    Lubiniecki AS; Shadle PJ
    Dev Biol Stand; 1997; 91():65-72. PubMed ID: 9413684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-process testing and limits.
    Sjöholm I
    Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685
    [No Abstract]   [Full Text] [Related]  

  • 12. International Conference on Harmonisation; guidance on Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2000 Dec; 65(251):83041-63. PubMed ID: 12356095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR; Luttkopf D; Seitz R; Vieths S
    Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality control and analytical techniques for biopharmaceuticals.
    Robinson CJ; Jones C
    Bioanalysis; 2011 Jan; 3(1):81-95. PubMed ID: 21175369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory expectation for data on viral testing and process evaluation for phase I studies and product licensing in the United States, Europe and Japan.
    Moriguchi H
    Dev Biol Stand; 1996; 88():143-7. PubMed ID: 9119127
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach.
    Vergote V; Burvenich C; Van de Wiele C; De Spiegeleer B
    J Pept Sci; 2009 Nov; 15(11):697-710. PubMed ID: 19750489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ICH4 and pharmacopoeias: similarities and differences].
    Artiges A
    Ann Pharm Fr; 1999 Mar; 57(2):161-7. PubMed ID: 10365473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.